What Are Pediatric Antidepressant Meta-Analyses Telling Clinical Practitioners? It Depends… by Zito, Julie M.
m
br
.s
yn
er
gi
es
pr
ai
ri
es
.c
a
96 || MBR || Volume : 1 || Issue : 2
commentary
What Are Pediatric Antidepressant Meta-Analyses 
Telling Clinical Practitioners? It Depends… 
Drews, Antonuccio and Kirsch pres-
ent a compelling case for questionable ef-
fectiveness based on a meta-analysis of 19 
randomized, double blind clinical trials 
among children and adolescents to evalu-
ate antidepressant (ATD) efficacy in several 
ATD subclasses, i.e. SSRI, SNRI and TCAs. 
The analysis expressed the summary effect 
size ‘d’ for drug-treated vs.  placebo-treated 
groups, after computing the effect size (pri-
mary endpoint minus baseline score divided 
by the pooled standard deviation).  The to-
tal ‘d’ was 1.62 for drug and 1.36 for placebo 
among all 19 studies for a between-group 
difference of 0.26, thus showing that 84% of 
drug effect is duplicated by placebo response. 
One might quibble about the value of add-
ing so many old TCA studies which were 
well documented by 1999 to lack evidence of 
benefit (Geller et al., 1999).  However, when 
the TCA studies were excluded, the 11 SSRI 
and SNRI studies showed placebo duplicated 
86% of the active drug response although the 
between group difference is ten-fold greater 
than when the TCAs were included.  Still, 
whether in all trials or only SSRI/SNRI trials 
the overall group benefit is slight, and statis-
tical significance does not equate with clini-
cal significance.
 If one further argues that clinical trial 
patients are more ideal than the community 
population that will be treated with an ATD, 
one’s skepticism of benefit grows because the 
trials favor more cooperative patients who 
may have had greater family expectation of 
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a positive drug effect, and may have achieved 
a level of benefit from the structure of the 
trial itself, i.e. providing regular contact with 
caring staff whose attention and champion-
ing support to complete the study may have 
added non-pharmacologic benefit.  Given the 
high placebo response in these youth, the net 
“trial effect” across all subjects might further 
contribute to the close response in the two 
groups.
In addition, one influential analysis 
showed that age-stratified benefit in children 
less than 12 years of age only favored fluox-
etine and concluded that SSRI benefits for 
MDD were moderated by age group, duration 
of depression and study conditions (Bridge et 
al., 2007).  
ATD safety concerns emerged in 2003–4 
and contribute to the importance of dem-
onstrating reliable ATD benefits in order to 
avoid unnecessary risk, as well as unneces-
sary monetary costs, a critically important 
point in tight economic times and runaway 
drug costs for brand name products.  The 
meta-analysis published by FDA investiga-
tors found that the safety signal based on sui-
cidality (thoughts, attempts or completions) 
was significantly greater for drug-treated 
compared with placebo-treated youth, albeit 
rare (4% vs 2%) and with no completed sui-
cides (Hammad et al., 2006).  A noted clinical 
trialist in ATDs has criticized the safety anal-
ysis in terms of the metric of using suicidal 
ideation as a surrogate for suicide because 
there is no measurable correlation between 
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suicidal thoughts and attempts or comple-
tions (Klein, 2006).  An additional concern 
is the extensive broadening of the warning 
to all ATDs although only SSRIs and SNRIs 
had data showing a concern.  Later warn-
ings extended to those less than 24 years old 
and to antiepileptic drugs, whether used as 
mood stabilizers or not.  These later deci-
sions, in the face of skepticism that the origi-
nal metrics were worthy of such interpreta-
tions, probably demonstrates the ‘cry wolf ’ 
syndrome—if all ATDs are equally risky, 
we might dismiss the risk issue completely. 
Labeling all ATD subclasses should not dis-
miss the uncertainty of safety for SSRIs and 
SNRIs.  Rather it should be interpreted as a 
call to action for (prospective) active surveil-
lance of a large well-diagnosed youth cohort, 
primarily adolescents, with well-described 
prior histories that stratify by severity of ill-
ness, in order to better address the risk ques-
tion in conjunction with data on benefit, 
length of exposure, dosing information, out-
comes and reasons for discontinuation.   
Several additional critical factors might 
be considered in relation to a physician’s de-
cision to use an ATD to treat pediatric de-
pression.  Among the factors I suggest should 
be included are:  1) Physician awareness of 
the controversies surrounding antidepres-
sant efficacy since their early development in 
the 1960s.  2) Drug safety from post-market-
ing surveillance and from clinical trial meta-
analysis of adverse drug event risk; 3) The 
general acceptance of biological psychiatry 
as a theory of psychiatric/behavioral abnor-
malities in a wide range of arenas.  These in-
clude research leaders, the lay public, and the 
media in conjunction with marketing and 
research in support of a biological theory, 
which persists despite inadequate evidence 
or flawed interpretation.  4) The growth of co-
morbid diagnoses in the evolving Diagnostic 
and Statistical Manual (DSM) and the dis-
tinctly differing professional perspectives 
depending on one’s primary discipline 
(Beutler & Malk, 2002).  5) The distinct role 
of the prescribing doctor now being limited 
to 15 minute ‘med check’ evaluations in con-
trast to the clinical psychologist’s role of psy-
chotherapist and referral for drug therapy. 
Added to this issue is the great variation in 
treatment settings and reimbursement sys-
tems.  These topics are briefly discussed in 
the context of this meta-analysis to assess 
benefit of pediatric antidepressant use over 
placebo in children and adolescents for the 
treatment of depression.
The antidepressant efficacy 
challenge
In 1985, Baldessarini’s review of TCAs for 
the treatment of adult depression concluded 
that trial support of a drug benefit was large-
ly restricted to severe (usually hospitalized) 
depression (Baldessarini, 1985).  The chal-
lenges for lesser depressions include sponta-
neous remission, response to psychotherapy 
and non-specific treatments e.g.  placebo 
and anxiolytics.  Thus, clinicians can mis-
takenly view the temporal association of 
drug use and improvement as causal.  These 
design issues are still true today for the new-
er subclasses of serotonin reuptake inhibi-
tors (SSRIs) and serotonin–norepinephrine 
reuptake inhibitors (SNRIs), and may be 
more so in youth, particularly young chil-
dren.  In summary, the high pediatric place-
bo response along with relatively greater ad-
verse events such as hostility and agitation/
activation, and greater dropout rates, make 
recommendations for ATD use in children 
for major depression questionable.  
Additional challenges reside in the limi-
tations of clinical trial methodology, the so-
called gold standard in medical care, with 
respect to selection bias; reductionist mea-
sures of diagnosis which rely more on cur-
rent symptoms than on past history and the 
degree of impairment; design modifications 
to strengthen positive results (Safer, 2002); 
and publication bias.  Investigators have 
questioned the merits of analyzing the pub-
lished trials when publication bias in phar-
macologic research is common and the esti-
mates of efficacy may essentially reside in the 
published studies (Whittington et al., 2004).
In the studies of efficacy in youth, there 
are important age-related distinctions in effi-
cacy of the SSRIs that are glossed over in the 
ensuing debate.  Safer’s secondary analysis 
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of published studies shows efficacy for ado-
lescents but not for children (Safer, 2006).  A 
similar finding for TCA efficacy was demon-
strated previously and concluded that TCAs 
are modestly effective in treating depression 
in adolescents, with concerns about side ef-
fects and safety further limiting their use 
(Hazell et al., 2002).
Drug safety concerns 
In general, the safety of pharmacologic 
agents is best studied after marketing be-
cause short-term use in drug trial popula-
tions does not generalize to long-term use 
in community-treated populations (Zito 
and Safer, 2007).  The limitations of the ex-
isting infrastructure for monitoring drug 
safety have been noted (Klein, 2006), not 
least of which is the absence of denomina-
tor data which makes systematic assessment 
of the risk (incident data) impossible.  These 
concerns have led to louder calls for active 
surveillance systems and the FDA’s sentinel 
initiative is, in part, an effort to improve as-
sessment of the risk of adverse drug events 
after marketing (Psaty and Charo, 2007).
Biological psychiatry as a 
theory of mental illness
The rise of biological psychiatry as a theory 
of mental illness since the 1980s has been ex-
traordinary.  It can be argued that a chicken 
and egg model confounds our understand-
ing.  Which came first, the drug mechanism 
of action affecting neurotransmitters or the 
newly define disease etiology? There is little 
doubt that medications have played an im-
portant role in reducing the suffering of those 
with severe conditions, e.g.  schizophrenia, 
bipolar disorder and in developmentally 
disabled children with self-injurious behav-
iors.  However, the mechanism of action of a 
drug, while necessarily connected to symp-
tom control and possibly reduced impair-
ment, is not sufficient to explain the cause 
of these problems.  Neurotransmitters are 
changed by drugs, e.g.  increasing serotonin 
at the synapse in depressives.  However, this 
change in brain chemistry does not make 
depression a serotonin deficiency condition. 
Nor is bipolar disorder a lithium-deficiency 
disorder.  Yet, these simplistic notions are 
exactly how the media and many patients 
and their families have come to understand 
psychopharmacology.  If unaddressed, there 
is a risk that such reductionist scientific 
thinking will lead to scientism rather than 
to critically important scientific evidence.   
The dsm-ification of child 
mental health
As the DSM classification system for mental 
illness is evolving, a major change is seen in 
the increase in comorbid conditions (Pincus 
et al., 2004).  This may be occurring because 
of an emphasis on the presence of symptoms 
derived from checklists and diminished 
emphasis on impairment.  Whatever ac-
counts for this change in comorbidities, the 
result in terms of medication treatments is 
clear — more comorbidities tends to produce 
more concomitant medication use.  More 
medication use increases the risk of adverse 
events, although clinicians may believe that 
2 drugs at lower doses reduce the risk of ad-
verse events from either alone at a higher 
dose.  There is no evidence to support this 
belief, although there are empirical stud-
ies supporting the notion that drug combi-
nations increase the prevalence of adverse 
events (Turner et al., 1998).  
Population, treatment 
setting and reimbursement 
systems
Across western society, there are radically 
different reimbursement systems which 
may affect the ability of a clinician to judge 
a drug-related outcome.  This is particu-
larly acute in the US health care system 
where patterns of continuity of care are not 
well known.  Its impact in pediatrics can 
be significant (Christakis et al., 2002).  For 
internalizing emotional health conditions, 
such as depression and anxiety, the failure 
to monitor symptom control and reduced 
impairment in subsequent time periods is 
troubling because new treatment-emergent 
symptoms may not be recognized as be-
havioral toxicity and mistakenly attributed 
to new symptoms of underlying pathol-
ogy (Zito et al., 2008).  In addition, when 
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patients move from provider to provider it 
is nearly impossible to avoid adding addi-
tional drugs in order to resolve what appear 
to be illness- related rather than drug-related 
(treatment-emergent) symptoms.  Systems 
based on primary catchment areas, as in the 
UK, maximize continuity of care and afford 
the best possible chance to gain experience 
in long-term effectiveness and safety of psy-
chopharmacologic agents.  
In the final analysis, the benefits and 
risks of drug treatment in community-based 
children and adolescents with mental disor-
ders should be viewed as a constantly moving 
target, once the FDA approval for marketing 
occurs.  As data and experience grow, the 
benefit–risk assessment is subject to change. 
Moreover, prescribing physicians and their 
patients each carry their own personal per-
spective on benefit/risk derived from vari-
ous pre and post marketing data, and the 
subsequent slowly emerging drug safety re-
ports from studies would help to identify the 
small but important subset of patients who 
cannot tolerate SSRIs.  This distinction is 
key in the decision to use drug therapy or to 
engage in non-drug alternatives including, 
when possible, watchful waiting. The experi-
ence of regular return visits would offer the 
opportunity for spontaneous remission or 
resolution of the precipitating symptoms to 
be recognized by the treating physician and 
help to make post-marketing surveillance of 
effectiveness and safety a reality. 
The meta-analysis of grouped ATD ben-
efits in children and adolescents presented 
by Drew, Antonuccio, and Kirsch helps cli-
nicians to appreciate that decisions to treat 
depression with an ATD relate to age, sever-
ity and prior history in their patients and 
calls for continuity of care and monitoring 
so that benefits and risks in the individual 
can be observed. Large prospective cohort 
studies would help to identify the small but 
important subset of patients who cannot tol-
erate  SSRIs.
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